Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron for Activation of Beige Adipose Tissue in Prediabetes
NCT04666636Phase 2Recruiting
- Start
- Dec 2020
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mirabegron in prediabetes (4 arms). Primary endpoints: Change in Glucose Tolerance at 16 weeks, Change in Body Composition at 16 weeks and 7 more. Started Dec 2020; status: recruiting.
02
Drugs
mirabegron
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT04666636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666636.